Inhibition of hepatitis C virus replication by antimonial compounds

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 10, 2005, Pages 4197-4202

  Hwang, Der Ren ^a,e   Lin, Ren Kuo ^a   Leu, Guang Zhou ^b   Lin, Tiao Yin ^b   Lien, Tzu Wen ^a   Yu, Ming Chen ^a   Yeh, Chau Ting ^c   Hsu, John T A ^a,d  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIMONY DERIVATIVE; ARSENIC TRIOXIDE; RIBAVIRIN; STIBOGLUCONATE SODIUM; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; HEPATITIS C; HEPATITIS C VIRUS; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; VIRUS HEPATITIS; VIRUS INHIBITION; VIRUS REPLICATION; WESTERN BLOTTING;

ANTIMONY; ANTIMONY SODIUM GLUCONATE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHLORIDES; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HEPACIVIRUS; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; LIVER NEOPLASMS; LUCIFERASES; VIRUS REPLICATION;

EID: 25844448779     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.10.4197-4202.2005     Document Type: Article

References (27)

1. al Jaser, M., A. el-Yazigi, M. Kojan, and S. L. Croft. 1995. Skin uptake, distribution, and elimination of antimony following administration of sodium stibogluconate to patients with cutaneous leishmaniasis. Antimicrob. Agents Chemother. 39:516-519.
2. Bachleitner-Hofmann, T., M. Kees, and H. Gisslinger. 2002. Arsenic trioxide: acute promyelocytic leukemia and beyond. Leuk. Lymphoma 43:1535-1540.
3. Baillie, A. J., G. H. Coombs, T. F. Dolan, and J. Laurie. 1986. Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate. J. Pharm. Pharmacol. 38:502-505.
4. Blight, K. J., A. A. Kolykhalov, and C. M. Rice. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974.
5. Choo, Q. L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362.
6. Chou, T.-C. 1991. The median effect principle and combination index for quantitation of synergism and antagonism, p. 61-102. In T.-C. Chou and D. C. Rideout (ed.), Synergism and antagonism in chemotherapy. Academic Press, San Diego, Calif.
7. Chulay, J. D., L. Fleckenstein, and D. H. Smith. 1988. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans. R. Soc. Trop. Med. Hyg. 82:69-72.
8. Davis, G. L., R. Esteban-Mur, V. Rustgi, J. Hoefs, S. C. Gordon, C. Trepo, M. L. Shiffman, S. Zeuzem, A. Craxi, M. H. Ling, J. Albrecht, et al. 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 339:1493-1499.
9. Hunter, C. A., T. F. Dolan, G. H. Coombs, and A. J. Baillie. 1988. Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. J. Pharm. Pharmacol. 40:161-165.
10. Hwang, D.-R., Y.-C. Tsai, J.-C. Lee, K.-K. Huang, R.-K. Lin, C.-H. Ho, J.-M. Chiou, Y.-T. Lin, J. T. A. Hsu, and C.-T. Yeh. 2004. Inhibition of hepatitis C virus replication by arsenic trioxide. Antimicrob. Agents Chemother. 48:2876-2882.
11. Jaser, M. A., A. el-Yazigi, and S. L. Croft. 1995. Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis. Pharm. Res. 12:113-116.
12. Jett, J. H. 1978. Mathematical analysis of DNA: histograms from asynchronous and synchronous cell populations, p. 93-102. In D. Lutz (ed.), Pulse cytophotometry. European Press, Brussels, Belgium.
13. Lauer, G. M., and B. D. Walker. 2001. Hepatitis C virus infection. N. Engl. J. Med. 345:41-52.
14. Lee, J. C., C. F. Chang, Y. H. Chi, D. R. Hwang, and J. T. Hsu. 2004. A reporter-based assay for identifying hepatitis C virus inhibitors based on subgenomic replicon cells. J. Virol. Methods 116:27-33.
15. Lee, J. C., Y. F. Shih, S. P. Hsu, T. Y. Chang, L. H. Chen, and J. T. Hsu. 2003. Development of a cell-based assay for monitoring specific hepatitis C virus NS3/4A protease activity in mammalian cells. Anal. Biochem. 316:162-170.
16. Leu, G. Z., T. Y. Lin, and J. T. Hsu. 2004. Anti-HCV activities of selective polyunsaturated fatty acids. Biochem. Biophys. Res. Commun. 318:275-280.
17. Lohmann, V., F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
18. McHutchison, J. G., and M. W. Fried. 2003. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin. Liver Dis. 7:149-161.
19. McHutchison, J. G., S. C. Gordon, E. R. Schiff, M. L. Shiffman, W. M. Lee, V. K. Rustgi, Z. D. Goodman, M. H. Ling, S. Cort, J. K. Albrecht, et al. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1485-1492.
20. Nieto, J., J. Alvar, A. B. Mullen, K. C. Carter, C. Rodríguez, M. I. San Andrés, M. D. San Andrés, A. J. Baillie, and F. González. 2003. Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals. Antimicrob. Agents Chemother. 47:2781-2787.
21. Tanabe, Y., N. Sakamoto, N. Enomoto, M. Kurosaki, E. Ueda, S. Maekawa, T. Yamashiro, M. Nakagawa, C. H. Chen, N. Kanazawa, S. Kakinuma, and M. Watanabe. 2004. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J. Infect. Dis. 189:1129-1139.
22. Walewski, J. L., T. R. Keller, D. D. Stump, and A. D. Branch. 2001. Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA 7:710-721.
23. Wasley, A., and M. J. Alter. 2000. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 20:1-16.
24. World Health Organization. 1997. Hepatitis C: global prevalence. Wkly. Epidemiol. Rec. 72:341-344.
25. Xu, Z., J. Choi, T. S. Yen, W. Lu, A. Strohecker, S. Govindarajan, D. Chien, M. J. Selby, and J. Ou. 2001. Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. EMBO J. 20:3840-3848.
26. Yeh, C. T., D. R. Hwang, H. Y. Lai, and J. T. Hsu. 2003. Inhibition of authentic hepatitis C virus replication by sodium stibogluconate. Biochem. Biophys. Res. Commun. 310:537-541.
27. Yi, T., M. K. Pathak, D. J. Lindner, M. E. Ketterer, C. Farver, and E. C. Borden. 2002. Anticancer activity of sodium stibogluconate in synergy with IFNs. J. Immunol. 169:5978-5985.